BCL9, a key transcriptional co-activator of the Wnt pathway and highly expressed in tumors, activates the Wnt/β-catenin signaling pathway by interacting with β-catenin, promoting its nuclear translocation, and promoting tumor progression 15. Here, BCL9 is linked to neoplasm.